文献速递细菌感染、耐药与抗菌药物

老药新用:西那卡塞通过破坏细胞膜抑制耐甲氧西林金黄色葡萄球菌并靶向IcaR抑制生物膜

Repurposing cinacalcet suppresses multidrug-resistant Staphylococcus aureus by disruption of cell membrane and inhibits biofilm by targeting IcaR.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本研究通过小分子药物库筛选非抗生素药物,发现FDA批准药物西那卡塞对金黄色葡萄球菌具有抗菌和抗生物膜活性,且细菌耐药性发展较少;动物模型显示其可改善肺炎模型生存率并促进生物膜感染模型细菌清除。机制涉及破坏膜靶向结构、改变能量代谢、产生活性氧,并靶向IcaR负调控IcaADBC抑制生物膜形成。

要点

  • 西那卡塞对金黄色葡萄球菌具有抗菌和抗生物膜活性,且细菌耐药性发展较少。
  • 西那卡塞改善肺炎模型生存率并促进生物膜感染模型细菌清除。
  • 西那卡塞靶向IcaR,通过负调控IcaADBC抑制生物膜形成。

核心结论

  • 西那卡塞有潜力老药新用作为耐多药金黄色葡萄球菌感染及相关生物膜的治疗药物,需进一步研究。

研究设计与样本

  • 利用小分子药物库筛选非抗生素药物的抗菌和抗生物膜特性,并通过动物模型评估体内疗效。
  • 采用定量蛋白质组学、生化试验、LiP-SMap、BLI检测和基因敲除技术研究抗菌机制。

主要发现

  • FDA批准药物西那卡塞对金黄色葡萄球菌显示抗菌和抗生物膜活性,且观察到细菌耐药性发展较少。
  • 西那卡塞显著改善肺炎模型生存率并促进生物膜感染模型细菌清除。
  • 西那卡塞的抗菌机制主要涉及破坏膜靶向结构、改变能量代谢和产生活性氧。
  • 西那卡塞靶向IcaR,通过负调控IcaADBC抑制生物膜形成。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MDR Staphylococcus aureus infections, along with the severity of biofilm-associated infections, continue to threaten human health to a great extent. It necessitates the urgent development of novel antimicrobial and antibiofilm agents. OBJECTIVES: To reveal the mechanism and target of cinacalcet as an antibacterial and antimicrobial agent for S. aureus. METHODS: Screening of non-antibiotic drugs for antibacterial and antibiofilm properties was conducted using a small-molecule drug library. In vivo efficacy was assessed through animal models, and the antibacterial mechanism was studied using quantitative proteomics, biochemical assays, LiP-SMap, BLI detection and gene knockout techniques. RESULTS: Cinacalcet, an FDA-approved drug, demonstrated antibacterial and antibiofilm activity against S. aureus, with less observed development of bacterial resistance. Importantly, cinacalcet significantly improved survival in a pneumonia model and bacterial clearance in a biofilm infection model. Moreover, the antibacterial mechanism of cinacalcet mainly involves the destruction of membrane-targeted structures, alteration of energy metabolism, and production of reactive oxygen species (ROS). Cinacalcet was found to target IcaR, inhibiting biofilm formation through the negative regulation of IcaADBC. CONCLUSIONS: The findings suggest that cinacalcet has potential for repurposing as a therapeutic agent for MDR S. aureus infections and associated biofilms, warranting further investigation.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Fang ZY, Zhang ZY, Zheng YD, et al. Repurposing cinacalcet suppresses multidrug-resistant Staphylococcus aureus by disruption of cell membrane and inhibits biofilm by targeting IcaR. J Antimicrob Chemother. 2024. PMID: 38412335. doi:10.1093/jac/dkae051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。